Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium

Koivula, Robert W.; Forgie, Ian M.; Kurbasic, Azra; Viñuela, Ana; Heggie, Alison; Giordano, Giuseppe N.; Hansen, Tue H.; Hudson, Michelle; Koopman, Anitra D. M.; Rutters, Femke

Published in: Diabetologia

Link to article, DOI: 10.1007/s00125-019-4906-1

Publication date: 2019

Document Version Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA): Koivula, R. W., Forgie, I. M., Kurbasic, A., Viñuela, A., Heggie, A., Giordano, G. N., ... the IMI-DIRECT consortium (2019). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 62(9), 1601-1615. https://doi.org/10.1007/s00125-019-4906-1

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium


Received: 13 July 2018 / Accepted: 10 April 2019 / Published online: 15 June 2019
© The Author(s) 2019

Abstract

Aims/hypothesis Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).

Methods From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6–24 months previously (n = 517) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at ~18 months (both cohorts) and at ~48 months (cohort 1) or ~36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe.

Results Using ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean ± SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m 2; fasting glucose 5.7 (0.6) mmol/l; 2 h glucose 5.9 (1.6) mmol/l. At the final follow-up examination the participants’ clinical characteristics were as follows: fasting glucose 6.0 (0.6) mmol/l; 2 h OGTT glucose 6.5 (2.0) mmol/l. In cohort 2 (diabetes), 66% (n = 331) were treated by lifestyle modification and 34% (n = 186) were treated with metformin plus lifestyle modification at enrolment. Fifty-eight per cent of participants in cohort 2 was male. Cohort 2 participants had the following characteristics at baseline: age 62 (8.1) years; BMI 30.5 (5.0) kg/m 2; fasting glucose 7.2 (1.4) mmol/l; 2 h glucose 8.6 (2.8) mmol/l. At the final follow-up examination, the

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00125-019-4906-1) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

* Ewan Pearson
e.z.pearson@dundee.ac.uk

* Paul W. Franks
paul.franks@med.lu.se

Extended author information available on the last page of the article
participants’ clinical characteristics were as follows: fasting glucose 7.9 (2.0) mmol/l; 2 h mixed-meal tolerance test glucose 9.9 (3.4) mmol/l.

Conclusions/interpretation The IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.

Keywords Diet · Ectopic fat · Genome · Glycaemic control · Insulin secretion · Insulin sensitivity · Personalised medicine · Physical activity · Prediabetes · Type 2 diabetes

Abbreviations

ALT Alanine aminotransferase
ASAT Abdominal subcutaneous adipose tissue
AST Aspartate aminotransferase
DIRECT Diabetes Research on Patient Stratification
fsOGTT Frequently sampled OGTT
GLP-1 Glucagon-like peptide-1
hpfVM High-pass-filtered vector magnitude
IAAT Intra-abdominal adipose tissue
IGR Impaired glucose regulation
IMI Innovative Medicines Initiative
MMTT Mixed-meal tolerance test
NGR Normal glucose regulation
OGIS Oral glucose insulin sensitivity
TAAT Total abdominal adipose tissue

Introduction

The global prevalence of type 2 diabetes is burgeoning. There is no cure, nor are there treatments effective enough to halt the progression of the disease. The burden the disease conveys at a societal and personal level is enormous, with an estimated world prevalence in 2017 of around 425 million people with type 2 diabetes and a further 352 million at risk of developing the disease [1]. The global cost of diagnosing and treating the disease and its complications in 2017 was estimated to be around €730 billion [1]. This bleak picture emphasises the profound shortcomings in our understanding of type 2 diabetes aetiology and pathogenesis, and the inadequate tools available with which to combat the disease.
Like some other complex diseases, the clinical presentation and prognosis of type 2 diabetes is heterogeneous. The risk conveyed by established diabetogenic factors such as obesity, physical inactivity and certain dietary components varies widely from one person to the next, as does the response to interventions targeting these risk factors. This is also true for those in whom diabetes is manifest, with response to glucose-lowering therapies, occurrence of adverse events and rates of progression being variable and hard to predict.

The diagnosis of type 2 diabetes is relatively straightforward, relying primarily on evidence of chronically elevated blood glucose concentrations [2]. However, elevated blood glucose concentrations can be the consequence of multiple defects in energy metabolism occurring across several organs and tissues [3–5] caused by myriad acquired or inherited factors. Thus, type 2 diabetes as currently defined characterises a collection of underlying pathologies [6], each with the common feature of elevated blood glucose that may require tailored therapies. The stratification of type 2 diabetes into treatable subclasses might be possible if accessible biomarkers of the disease’s underlying pathologies were known.

Although improving the management of type 2 diabetes through subclassification may lead to more focused treatment, susceptibility to risk factors and response to treatments also vary. Thus, stratifying patient populations into subgroups defined using biomarkers quantifying susceptibility to risk factors and responsiveness to specific therapeutics would further enhance our ability to treat and ideally prevent the disease.

The Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) Consortium is a collaboration among investigators from some of Europe’s leading academic institutions and pharmaceutical companies [7]. The overarching objective of IMI DIRECT is to discover and validate biomarkers of glycaemic deterioration before and after the onset of type 2 diabetes. To this end, we established two new multicentre prospective cohort studies comprised of adults from northern Europe at risk of or with recently diagnosed type 2 diabetes. Within these cohorts, a comprehensive array of risk factors, intermediate phenotypes and metabolic outcomes were repeatedly assessed using cutting-edge technologies. The richly phenotyped IMI DIRECT cohorts will facilitate the discovery of biomarkers for glycaemic control in individuals at risk of or with type 2 diabetes.

Here we describe the characteristics of the two IMI DIRECT cohorts at baseline and at the two major follow-up visits up to 48 months later, to provide context for those subsequently analysing and reviewing studies based on these data. We also consider these results in the context of the implemented protocols and plans outlined at the beginning of the project, as described previously [7].

Methods

The rationale and design of the epidemiological cohorts within IMI DIRECT are reported elsewhere [7]; here we provide data and information about key variables and methods, respectively, that were not described in the rationale and design paper published previously.

Approval for the study protocol was obtained from each of the regional research ethics review boards separately and all participants provided written informed consent at enrolment. The research conformed to the ethical principles for medical research involving human participants outlined in the declaration of Helsinki.

Recruitment, enrolment and eligibility The derivations of cohort 1 and cohort 2 are shown in Fig. 1. The sampling frame for cohort 1 comprised four existing prospective cohort studies: Metabolic Syndrome in Men (METSIM, Finland) [8]; Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) [9], Hoorn Meal Study (HMS) and New Hoorn Study (NHS) [10] (Netherlands); Health2010 [11], Health2006 [12], Danish Study of Functional Disorders (DanFunD) [13] and Gut, Grain and Greens (GGG) [14] studies (Denmark) and Malmö Diet and Cancer (MDC) study (Sweden) [15]. Participants for cohort 2 were identified through general practice and other registries, as described previously [7].

After excluding participants who did not meet the inclusion criteria or whose data failed quality control, a total of 2127 participants at risk of diabetes and 789 participants with type 2 diabetes were retained in cohort 1 and cohort 2, respectively. In cohort 1, emphasis was placed on recruiting participants deemed at high risk of type 2 diabetes according to ADA 2011 HbA1c criteria (HbA1c 40–48 mmol/mol [5.7–6.4%]) [2, 7]. As anticipated during the design phase, the sampling frame contained too few participants that fulfilled this criterion; thus, we proceeded to enrol participants with progressively lower HbA1c concentrations, who were also considered at highest risk of glycaemic deterioration according to the DIRECT-DETECT risk algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) applied to the parent cohort sampling frame [7, 16].

In cohort 1, 1989 (93%) participants enrolled at baseline also attended the first major follow-up visit at a mean of 18.6 (SD 1.4) months and 1729 (81%) attended the final follow-up visit 30.8 (SD 1.3) months later. In cohort 2, 668 (85%) participants enrolled at baseline attended their first major follow-up visit at 18.2 (SD 0.6) months and 552 (70%) attended the final follow-up visit 18.2 (SD 1.0) months later.

Glycaemic biochemistry assays Plasma glucose, insulin and C-peptide assays for cohort 1 were carried out centrally at the University of Eastern Finland (Kuopio, Finland), where
plasma glucose was analysed using the enzymatic glucose hexokinase method and photometric measurement on Konelab 20 XT Clinical Chemistry analyser (Thermo Fisher Scientific, Vantaa, Finland). In cohort 2, plasma insulin and C-peptide were analysed using chemiluminometric immunoassay (CLIA) (Liaison Insulin [DiaSorin, Saluggia, Italy] and Liaison C-peptide [DiaSorin]). The instrument used was DiaSorin Liaison Analyser (DiaSorin Deutschland, Dietzenbach, Germany). Plasma glucose, insulin and C-peptide assessments for cohort 2 were carried out centrally at the University of Exeter (Exeter, UK). Assessments of HbA1c, blood lipids, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) for both cohorts were carried out centrally at the University of Exeter. Glucose was measured by the enzymatic colorimetric assay GOD-PAP using Roche MODULAR P analysers (Hoffmann-La Roche, Basel, Switzerland). Insulin was measured by electrochemiluminescence using Roche E170 Analysers (Hoffmann-La Roche). C-peptide concentrations in plasma and urine were measured by electrochemiluminescence using Roche E170 Analysers (Hoffmann-La Roche). HbA1c was measured by ion-exchange high-performance liquid chromatography using Tosoh G8 analysers (Tosoh Bioscience, San Francisco, CA, USA). Each biochemical assay was performed using validated standard methods. Reference samples were included in all procedures to control for inter-assay variation and laboratories regularly participated in international external quality assessment schemes. In addition, a subset of samples was assayed for C-peptide, insulin and glucose on both sites to assess inter-laboratory variation.

**Blood lipid and liver enzyme biochemistry assays**

Triacylglycerol was measured by quantitative determination with glycerol blanking. HDL-cholesterol was measured directly using polyethylene glycol-modified enzymes and dextran sulphate. When cholesterol esterase and cholesterol oxidase enzymes are modified by polyethylene glycol, they show selective catalytic activity towards lipoprotein fractions, with reactivity increasing in the order LDL < VLDL ≈ chylomicrons < HDL. Total cholesterol was measured by an enzymatic, colorimetric method. LDL-cholesterol was calculated from the total cholesterol, HDL-cholesterol and triacylglycerol concentrations using the Friedewald formula: LDL = total cholesterol – HDL-cholesterol – (triacylglycerol/2.2). ALT and AST were measured by UV absorbance without pyridoxal phosphate activation. ALT, AST, cholesterol, glucose, triacylglycerol and HDL-cholesterol were measured using a Roche MODULAR P analyser (Roche Diagnostics, Indianapolis, IN, USA). Insulin and C-peptide were measured using a Roche E170 analyser (Roche Diagnostics).
Blood glucagon-like peptide-1 assays Plasma concentrations of glucagon-like peptide-1 (GLP-1) were determined by drawing blood samples collected at two different time points (0 and 60 min) during the 75 g frequently sampled OGTT (fSGTT) mixed-meal tolerance test (MMTT) (baseline samples only). P800 tubes (Becton Dickinson, Wokingham, UK) were used to provide immediate protection from intrinsic proteolysis. Quantitative determination of active GLP-1 was achieved using MSD GLP-1 active kit (product code K150JWC; Meso Scale Diagnostics, Rockville, MD, USA). Total GLP-1 was assayed using MSD GLP-1 total kit (product code K150JVC; Meso Scale Diagnostics).

Abdominal MRI analyses The volume of adipose tissue was measured in litres using MRI, as described elsewhere [17]. Total abdominal adipose tissue (TAAT) may be separated into intra-abdominal adipose tissue (IAAT), also known as ‘visceral’ fat, and abdominal subcutaneous adipose tissue (ASAT). IAAT is the volume of adipose tissue within the abdominal cavity, TAAT is the sum of IAAT and ASAT. Liver and pancreas fat and iron (T2*) were derived simultaneously using a multiecho MRI technique, as previously described [17, 18]. This method has the advantage over single voxel MR spectroscopy in that regional differences in ectopic fat distribution can be measured. Furthermore, it is often possible to obtain a single slice quantification of the liver and pancreas, allowing simultaneous measurement of fat and iron within two separate organs. A biexponential curve-fitting model was used to derive the relative signal contributions from fat and water from the many images normally obtained with the multiecho sequence. Briefly, tissue with no fat infiltration generates a very smooth decay curve, whereas tissue containing a higher level of fat is characterised by significant oscillations throughout the decay curve [18]. A further output from the multiecho technique is T2* tissue values; as changes in these are indicative of iron content, this provides a clinically relevant additional measurement. Tissue iron concentration (mg/d dry weight tissue) was estimated from T2* using a validated model [19].

Diet assessment Self-reported dietary intake was assessed by a 24 h multi-pass method, using food habit and 24 h recall questionnaires. Analysis of these diet data was undertaken using Dietplan-6 (version 6.70.43, 2013; Forestfield Software, Horsham, UK). The specific analysis methods are described in detail elsewhere [7]. We also objectively assessed diet using discriminative metabolite signatures, an approach described in detail elsewhere [20]. Briefly, each participant’s serum metabolite profile was obtained using a targeted metabolomics assay (AbsoluteIDQ p180 Kit; BIOCRADES Life Sciences, Innsbruck, Austria), which simultaneously quantifies 188 metabolites. In a previously published diet intervention study [20], serum samples had been collected in 19 participants who had undergone a metabolic ward-based supervised diet intervention. We assayed these blood samples using the BIOCRADES AbsoluteIDQ p180 Kit and derived diet-discriminatory metabolomic signatures, using previously described methods [20]. These data were then used to predict the dietary characteristics of the IMI DIRECT study participants.

Physical activity assessment Objective measures of physical activity were derived from triaxial accelerometers (ActiGraph GT3X+/GT3X+w/GT3X+bt; ActiGraph Co., Pensacola, FL, USA) as described previously [7]. Raw data files (.gt3x) were converted to comma separated value (.csv) format storing rawest possible accelerations for each axis at a resolution of 30 Hz using ActiLife 6 (version 6.11.5; ActiGraph Co.). All inferred measures of physical activity were calculated using PAMPRO (version uploaded 21 Oct 2015; MRC Epidemiology unit, Cambridge, UK), custom open source software available under public license (https://github.com/Thomite/pampro). Data from each axis of acceleration was auto-calibrated to local gravity. Non-wear was inferred as a vector magnitude SD of less than 4 mg for a consecutive period greater than 60 min. All measures presented here have been adjusted for diurnal rhythm to account for bias from non-wear removal. However, due to the wear method (non-dominant wrist fastened using the manufacturer’s non-removable hospital band), intermittent non-wear time was rare. The main physical activity estimates presented here are high-pass-filtered vector magnitude (hpfVM), which infers intensity of participants’ movement in any direction at any given time (here, averaged during wear period). Time spent in established physical activity intensities by physical activity energy expenditure was estimated using calculated hpfVM cutpoints: sedentary (<48 m hpfVM), light (48–154 mg hpfVM), moderate (154–389 mg hpfVM) and vigorous (>389 mg hpfVM). The methods used to infer these measures have been validated and described in detail elsewhere [21].

DNA extraction and genotyping DNA extraction was carried out using Maxwell 16 Blood DNA purification kits and a Maxwell 16 semi-automated nucleic acid purification system (Promega, Southampton, UK). Genotyping was conducted using the Illumina HumanCore array (HCE24 v1.0) and genotypes were called using Illumina’s GenCall algorithm. Samples were excluded for any of the following reasons: call rate <97%; low or excess mean heterozygosity; sex discordance and monozygosity. Genotyping quality control was then performed to provide high-quality genotype data for downstream analyses using the following criteria: call rate <99%; deviation from Hardy–Weinberg equilibrium (exact p < 0.001); variants not mapped to human genome build GRCh37 and variants with duplicate chromosome positions (a total of 30,318 markers were excluded). A total of 3032
samples and 517,958 markers across the two studies passed quality control procedures. We took autosomal variants with MAF >1% that passed quality control and constructed axes of genetic variation using principal components analysis implemented in the GCTA (version 1.24.4, downloaded from https://cnsgenomics.com/software/gcta/#Download) software to identify ethnic outliers defined as non-European ancestry using the 1000 Genomes samples as reference. We identified six individuals as ethnic outliers.

Additional measures (not presented here) Biomarker discovery analyses using these data also employ additional measures (including 'omic' measures), which are outside the scope of this cohort description. Additional measures that are not described here include transcriptomics (RNA sequencing from fasting whole blood), microbiomics (DNA isolation and deep sequencing in faecal samples), proteomics (targeted array in fasting plasma) and metabolomics (targeted and untargeted assays in fasting plasma). GAD/islet antigen-2 assessments from fasting serum samples were also undertaken. Data from the Recent Physical Activity Questionnaire (RPAQ) and sleep diaries were also collected in subcohorts.

Statistical power of study A detailed section on sample size and power for the study is available in the previously published rationale and design paper [7]. Briefly, statistical power will vary depending on a number of factors specific to the analysis to be carried out, such as biomarker effect sizes, variance/frequency of outcome and biomarker, statistical modelling methods employed, number of tests (multiple testing adjustment) and of course sample size, available for the relevant variables included in the model. The dataset will therefore be well powered for some analyses while it may be underpowered for other analyses and will thus be covered in detail for the specific scenarios in subsequent analyses.

Statistical methods for descriptive data Based on ADA 2011 diagnostic criteria, impaired fasting plasma glucose is 5.6–6.9 mmol/l (100–125 mg/dl), impaired glucose tolerance is 2 h 75 g OGTT plasma glucose 7.8–11.0 mmol/l (140–199 mg/dl) and prediabetes HbA1c is 40–48 mmol/mol (5.7–6.4%) [2]. Accordingly, below and above these cut-offs was considered ‘normal’ and ‘diabetic’ ranges, respectively. Cohort 1 was stratified into two categories of blood glucose level: normal glucose regulation (NGR) and impaired glucose regulation (IGR). NGR was defined as the HbA1c, fasting glucose and 2 h glucose values being within the normal ranges for each measure. IGR was defined as there being impaired values in at least one of HbA1c, fasting glucose or 2 h glucose. Cohort 2 was stratified into treatment categories: lifestyle advice only or metformin plus lifestyle advice. Descriptive statistics are presented as mean ± SD. Pairwise Pearson correlations were calculated for all key variables described here. For these analyses, continuous variables were first inverse normal transformed and then adjusted for age, sex and study centre by two-step residual regression. We present the same type of data for anthropometric and glycaemic variables for the main follow-up visits, as well as the differences for these variables between the baseline and the final follow-up visit measures (follow-up Δ = final follow-up value – baseline value). We also calculated pairwise Pearson correlations for the follow-up Δ values; for these analyses, continuous variables were first inverse normal transformed and then adjusted for age, sex, study centre and days since baseline visit by two-step residual regression. All statistics were computed using R software version 3.4.0 [22]. The IMI DIRECT data release version used for the analyses in this article was direct_03-29-2019.

Glycaemic trait modelling Glycaemic traits were derived from the 75 g fsOGTT (sampling at 0, 15, 30, 45, 60, 90, 120 min) and MMTT (sampling at 0, 30, 60, 90, 120 min) for cohort 1 and cohort 2, respectively. Analyses used a mathematical model that describes the relationship between insulin secretion and glucose concentration [23, 24]. The model expresses insulin secretion as the sum of two components, the first of which represents the dependence of insulin secretion on absolute glucose concentration at any time during the fsOGTT/MMTT, through a dose–response function. Characteristic parameters of the dose–response relationship are the mean slope over the observed glucose range, denoted as glucose sensitivity. The dose–response relationship is modulated by a potentiation factor, which accounts for the fact that during acute stimulation, insulin secretion is higher on the descending phase of hyperglycaemia than at the same glucose concentration on the ascending phase. In participants with NGR and normal insulin secretion, the potentiation factor typically increases from baseline to the end of a 2 h OGTT [25]. To quantify this excursion, the ratio between the 2 h and the baseline value was calculated. This ratio is denoted as potentiation ratio and reflects late insulin release. The second insulin secretion component represents the dependence of insulin secretion on the rate of change of glucose concentration. This component is termed derivative component and is determined by a single parameter, denoted as rate sensitivity. Rate sensitivity reflects early insulin release [25]. The model parameters were estimated from glucose and C-peptide concentrations by regularised least-squares, as previously described [23]. Regularisation involves the choice of smoothing factors, which were selected to obtain glucose and C-peptide model residuals with SDs close to expected measurement error (~1% for glucose and ~4% for C-peptide). Insulin secretion rates were calculated from the model every 5 min. The integral of insulin secretion during the fsOGTT was denoted as total insulin output.

The validity of the fsOGTT and MMTT for the assessment of insulin sensitivity has been shown in the original
## Table 1 Baseline clinical and phenotypic characteristics of cohorts 1 and 2

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cohort 1 (prediabetes)</th>
<th>Cohort 2 (diabetes)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Value</td>
<td>n</td>
</tr>
<tr>
<td>Male sex, %</td>
<td>76</td>
<td>2127</td>
</tr>
<tr>
<td>Time since screening visit, months</td>
<td>6.4 (4.8)</td>
<td>2127</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62 (6.2)</td>
<td>2127</td>
</tr>
<tr>
<td>Height, cm</td>
<td>174 (8)</td>
<td>2127</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>85 (13)</td>
<td>2127</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>99 (11)</td>
<td>2127</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>27.9 (4.0)</td>
<td>2127</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg</td>
<td>131 (15)</td>
<td>2107</td>
</tr>
<tr>
<td>Diastolic blood pressure, mmHg</td>
<td>81 (9.0)</td>
<td>2107</td>
</tr>
<tr>
<td>HbA1c, mmol/mol</td>
<td>37 (2.9)</td>
<td>2113</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>5.5 (0.3)</td>
<td>2113</td>
</tr>
<tr>
<td>Fasting glucose, mmol/l</td>
<td>5.7 (0.6)</td>
<td>2126</td>
</tr>
<tr>
<td>Fasting insulin, pmol/l</td>
<td>78.2 (54.5)</td>
<td>2124</td>
</tr>
<tr>
<td>Fasting HDL-cholesterol, mmol/l</td>
<td>1.3 (0.4)</td>
<td>2123</td>
</tr>
<tr>
<td>Fasting LDL-cholesterol, mmol/l</td>
<td>3.2 (0.9)</td>
<td>2123</td>
</tr>
<tr>
<td>Fasting triacylglycerol, mmol/l</td>
<td>1.4 (0.6)</td>
<td>2123</td>
</tr>
<tr>
<td>ALT, U/l</td>
<td>18 (12)</td>
<td>2120</td>
</tr>
<tr>
<td>AST, U/l</td>
<td>27 (10)</td>
<td>2052</td>
</tr>
<tr>
<td>Total cholesterol, mmol/l</td>
<td>5.1 (1)</td>
<td>2123</td>
</tr>
<tr>
<td>Fasting intact GLP-1 concentration, pg/ml</td>
<td>0.41 (0.59)</td>
<td>2121</td>
</tr>
<tr>
<td>Fasting total GLP-1 concentration, pg/ml</td>
<td>6.5 (4.4)</td>
<td>2120</td>
</tr>
<tr>
<td>Fasting glucagon, pg/ml</td>
<td>98 (41)</td>
<td>2116</td>
</tr>
<tr>
<td>1 h intact proinsulin, pg/ml</td>
<td>19 (11.7)</td>
<td>578</td>
</tr>
<tr>
<td>1 h GLP-1 increment, pg/ml</td>
<td>9.3 (12.1)</td>
<td>2103</td>
</tr>
<tr>
<td>1 h glucagon increment, pg/ml</td>
<td>−10.7 (38)</td>
<td>2097</td>
</tr>
<tr>
<td>Mean 2 h glucose, mmol/l</td>
<td>7.7 (1.5)</td>
<td>2126</td>
</tr>
<tr>
<td>Mean 2 h insulin, pmol/l</td>
<td>383 (260)</td>
<td>2126</td>
</tr>
<tr>
<td>2 h glucose, mmol/l</td>
<td>5.9 (1.6)</td>
<td>2127</td>
</tr>
<tr>
<td>2 h insulin, pmol/l</td>
<td>48 (48)</td>
<td>2102</td>
</tr>
<tr>
<td>Fasting insulin secretion, pmol min⁻¹ m⁻²</td>
<td>106 (40)</td>
<td>2126</td>
</tr>
<tr>
<td>Integral of total insulin secretion, nmol/m²</td>
<td>52 (18)</td>
<td>2126</td>
</tr>
<tr>
<td>Glucose sensitivity, pmol min⁻¹ m⁻² (mmol/l)⁻¹</td>
<td>113 (55)</td>
<td>2126</td>
</tr>
<tr>
<td>Rate sensitivity, pmol m⁻² (mmol/l)⁻¹</td>
<td>921 (699)</td>
<td>2126</td>
</tr>
<tr>
<td>Potentiation factor ratio, dimensionless</td>
<td>1.7 (0.6)</td>
<td>2126</td>
</tr>
<tr>
<td>Insulin sensitivity (2 h OGIS), ml min⁻¹ m⁻²</td>
<td>381 (59)</td>
<td>2118</td>
</tr>
<tr>
<td>Stumvoll insulin sensitivity index, ml min⁻¹ kg⁻¹</td>
<td>7.8 (2.4)</td>
<td>2099</td>
</tr>
<tr>
<td>Matsuda insulin sensitivity index, arbitrary units</td>
<td>5 (3.1)</td>
<td>2126</td>
</tr>
<tr>
<td>IAAT, l</td>
<td>5.5 (2.4)</td>
<td>956</td>
</tr>
<tr>
<td>ASAT, l</td>
<td>6.1 (2.6)</td>
<td>953</td>
</tr>
<tr>
<td>TAAT, l</td>
<td>12 (3.9)</td>
<td>953</td>
</tr>
<tr>
<td>Liver fat, %</td>
<td>5 (4.7)</td>
<td>959</td>
</tr>
<tr>
<td>Pancreatic fat, %</td>
<td>13 (8.9)</td>
<td>929</td>
</tr>
<tr>
<td>Liver iron content, mg/g tissue</td>
<td>1.3 (0.26)</td>
<td>958</td>
</tr>
<tr>
<td>Pancreatic iron content, mg/g tissue</td>
<td>1.3 (0.43)</td>
<td>927</td>
</tr>
<tr>
<td>Mean physical activity intensity: hpfVM, mg</td>
<td>37 (10.2)</td>
<td>1714</td>
</tr>
<tr>
<td>Sedentary, % of time</td>
<td>82 (4.2)</td>
<td>1714</td>
</tr>
<tr>
<td>Light physical activity, % of time</td>
<td>10.9 (2.3)</td>
<td>1714</td>
</tr>
<tr>
<td>Moderate physical activity, % of time</td>
<td>5.3 (1.5)</td>
<td>1714</td>
</tr>
<tr>
<td>Vigorous physical activity, % of time</td>
<td>1.5 (0.7)</td>
<td>1714</td>
</tr>
<tr>
<td>Total energy intake, kJ/day</td>
<td>8213 (3142)</td>
<td>2064</td>
</tr>
<tr>
<td>Carbohydrate intake, g/day</td>
<td>223 (96)</td>
<td>2064</td>
</tr>
<tr>
<td>Fat intake, g/day</td>
<td>79 (39)</td>
<td>2064</td>
</tr>
<tr>
<td>Protein intake, g/day</td>
<td>99 (44)</td>
<td>2064</td>
</tr>
<tr>
<td>Sugar intake, g/day</td>
<td>96 (53)</td>
<td>2064</td>
</tr>
<tr>
<td>Fibre intake, g/day</td>
<td>20 (9.8)</td>
<td>2064</td>
</tr>
<tr>
<td>Saturated fat intake, g/day</td>
<td>29 (16)</td>
<td>2064</td>
</tr>
<tr>
<td>Monounsaturated fat intake, g/day</td>
<td>27 (17)</td>
<td>2064</td>
</tr>
<tr>
<td>Polyunsaturated fat intake, g/day</td>
<td>13 (8.2)</td>
<td>2064</td>
</tr>
</tbody>
</table>

Data are mean (SD) except for sex, which is n%, and reflect the data available at the time of publication.

Values are untransformed and unadjusted.
publications presenting the indices [26–28]. In the studies, the OGTT/MMTT indices are compared with values obtained by euglycaemic glucose clamp. The validity of the beta cell function model is supported by numerous studies [25]. For beta cell function, it is not possible to validate an OGTT/MMTT method against the classical tests with glucose intravenous infusion, due to the presence of the incretin effect. However, it has been shown that the estimated beta cell dose–response is consistent with the graded glucose infusion test across the spectrum of glucose tolerance [29, 30].

Results

Cohort 1 (prediabetes) Of 2235 enrolled participants in cohort 1, 2127 passed all inclusion, exclusion and quality control criteria. Of these, 1419 (67%) had IGR according to at least one ADA category for HbA1c, fasting glucose or 2 h glucose [2] and were thus within the target ‘prediabetes’ range. A total of 693 participants (33% of cohort 1) displayed NGR according to all three glycaemic measures. Participants with prevalent type 2 diabetes (n = 105) or who withdrew from the study (n = 3) were excluded from further analyses.

The number of participants enrolled into cohort 1 varied between centres, with the Finnish subcohort being the largest (providing 58% [n = 1240]) of the total cohort 1 baseline sample. The other centres in the Netherlands, Denmark and Sweden enrolled 22% (n = 473), 13% (n = 275) and 7% (n = 139) of the total cohort, respectively.

The ratio of men to women varied in each subcohort, with all participants at the Finnish centre being male, and 43%, 45% and 29% being male in the subcohorts from the Netherlands, Denmark and Sweden, respectively.

Detailed participant baseline characteristics for cohort 1 are shown in Table 1 (and stratified by glycaemic category in electronic supplementary material [ESM] Table 1). Figure 2 shows the pairwise correlations between a selection of key phenotypic variables at baseline. Participant characteristics at the follow-up visits and the difference (Δ) between baseline and final follow-up for cohort 1 are shown in Table 2. The pairwise correlations between the baseline to final follow-up difference for anthropometric and glucose-control variables are shown in Fig. 3.

Briefly, at baseline, participants had a mean (SD) age of 62 (6.2) years, BMI 27.9 (4.0) kg/m², HbA1c 37 (2.9) mmol/mol [5.5 (0.27)%], fasting glucose 5.7 (0.6) mmol/l, 2 h glucose 5.9 (1.6) mmol/l, fasting insulin 10.9 (7.6) pmol/l, glucose sensitivity 113 (55) pmol min⁻¹ m⁻² (mmol/l)⁻¹ and insulin sensitivity (2 h oral glucose insulin sensitivity [OGIS]) 381 (59) ml min⁻¹ m⁻². Participants had a 0–48 month mean (SD) difference in fasting plasma glucose levels of 0.3 (0.2) mmol/l.

Fig. 2 Pairwise correlation matrix. Fill colour indicates Pearson correlation coefficient (r), where positive is denoted by red fill, inverse by blue fill and magnitude by intensity. Cohorts 1 and 2 are separate, above and below the diagonal, respectively. All continuous variables were normally transformed and adjusted for age, sex and study centre. ActGLP1min0, fasting intact GLP-1 concentration; BasallSR, fasting insulin secretion; CHOI, carbohydrate hydrolyse; Chol, total cholesterol; DBP, diastolic blood pressure; FatI, fat intake; Fibrel, fibre intake; Glucagonmin0, fasting glucagon; Glucose, fasting glucose; GlucoseSens, glucose sensitivity; HDL, fasting HDL-cholesterol; IncGLP1min60, 1 h GLP-1 increment; IncGlucagonmin60, 1 h glucagon increment; Insulin, fasting insulin; LDL, fasting LDL-cholesterol; LiverFat, liver fat; LiverIrn, liver iron content; LPA, light physical activity (% of time); Matsuda, Matsuda insulin sensitivity index; MeanGlucose, mean 2 h glucose; MeanInsulin, mean 2 h insulin; MPA, moderate physical activity (% of time); MUFatI, monounsaturated fat intake; OGIS, 2 h insulin sensitivity; PA, mean physical activity intensity; hpNVM; PancFat, pancreatic fat; PancIrn, pancreatic iron content; PFR, potentiation factor ratio; Prolnsnmmin60, 1 h intact proinsulin; ProteinI, protein intake; PUFatI, polyunsaturated fat intake; RateSens, rate sensitivity; SatFatI, saturated fat intake; SBP, systolic blood pressure; SPA, sedentary (% of time); Stumvoll, Stumvoll insulin sensitivity index; SugarI, sugar intake; TEL, total energy intake; TG, fasting triacylglycerol; TotalIrn, integral of total insulin secretion; TotGLP1min0, fasting total GLP-1 concentration; TwoGlucose, 2 h glucose; Twolnulin, 2 h insulin; VPA, vigorous physical activity (% of time)

Cohort 2 (diabetes) Of 830 individuals in cohort 2 enrolled to attend the screening visit, 789 passed all inclusion, exclusion and quality control criteria. Of these, 272 were treated with lifestyle modification plus metformin and 517 were treated with lifestyle intervention only. Participants who withdrew consent, who were receiving any other oral hypoglycaemic agent or who reported ever receiving insulin treatment were excluded (n = 41).

Of the participants in cohort 2 at baseline, the UK (Dundee, Exeter, Newcastle), Dutch (Amsterdam), Swedish (Lund) and Danish (Copenhagen) study centres enrolled 21% (n = 167), 18% (n = 141), 21% (n = 166), 21% (n = 167), 12% (n = 96) and 7% (n = 52) of the total cohort, respectively; 52–63% of the subcohort participants were male.

Detailed participant characteristics and key variables for cohort 2 at baseline are shown in Table 1 (and stratified by treatment category in ESM Table 1). Figure 2 shows the pairwise correlation matrix for key variables at baseline adjusted for age, sex and study centre. Participant characteristics for follow-up visits and the difference between the baseline and final follow-up visit (Δ) for cohort 2 are shown in Table 2. A pairwise correlation matrix for the anthropometric and glucose-control Δ variables are shown in Fig. 3.

Briefly, at baseline, participants had a mean (SD) age 62 (8.1) years, BMI 30.5 (5.0) kg/m², HbA1c 46.5 (5.8) mmol/mol [6.4 (0.53)%], fasting glucose 7.2 (1.4) mmol/l, 2 h glucose 8.6 (2.8) mmol/l, fasting insulin 107 (71) pmol/l, glucose sensitivity 83 (55) pmol min⁻¹ m⁻² (mmol/l)⁻¹ and insulin sensitivity (2 h OGIS) 298 (69) ml min⁻¹ m⁻².
Participants had a 0 months to 18 months mean difference in fasting plasma glucose levels of 0.8 (1.9) mmol/l.

**Genetic population substructure** As some study centres enrolled participants into both cohorts, we elected to characterise the genetic population substructure across the cohorts by study centre (i.e. pooling both cohorts at a given centre where possible). Genetic substructures closely map to the geographic location of the populations [31], indicating ethnic homogeneity within regions from which the cohorts were recruited, whereas there is far greater heterogeneity between centres, the latter driven mainly by the inclusion of Finnish participants. This is illustrated in Fig. 4 where Finnish participants form a distinct cluster (to the north east) compared with the population from the other cohorts.
## Table 2  Follow-up and follow-up Δ in clinical and phenotypic characteristics of cohorts 1 and 2

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cohort 1 (prediabetes)</th>
<th>Cohort 2 (diabetes)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>18 Months</td>
<td>48 Months</td>
</tr>
<tr>
<td></td>
<td>Value</td>
<td>n</td>
</tr>
<tr>
<td>Male sex, %</td>
<td>77</td>
<td>1989</td>
</tr>
<tr>
<td>Time since previous visit, months</td>
<td>18.6 (1.4)</td>
<td>1989</td>
</tr>
<tr>
<td>Age, years</td>
<td>63.6 (6.1)</td>
<td>1989</td>
</tr>
<tr>
<td>Height, cm</td>
<td>174 (7.9)</td>
<td>1983</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>85 (13.5)</td>
<td>1981</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>99 (11)</td>
<td>1981</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>27.9 (4)</td>
<td>1980</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg</td>
<td>131 (16)</td>
<td>1983</td>
</tr>
<tr>
<td>Diastolic blood pressure, mmHg</td>
<td>80 (8.8)</td>
<td>1983</td>
</tr>
<tr>
<td>HbA1c, mmol/mol</td>
<td>37.9 (3.1)</td>
<td>1980</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>5.6 (0.3)</td>
<td>1980</td>
</tr>
<tr>
<td>Fasting glucose, mmol/l</td>
<td>5.6 (0.6)</td>
<td>1977</td>
</tr>
<tr>
<td>Fasting insulin, pmol/l</td>
<td>84.7 (61.7)</td>
<td>1975</td>
</tr>
<tr>
<td>2 h glucose, mmol/l</td>
<td>6.1 (1.7)</td>
<td>1975</td>
</tr>
<tr>
<td>2 h insulin, pmol/l</td>
<td>55.3 (53.7)</td>
<td>1950</td>
</tr>
<tr>
<td>Mean 2 h glucose, mmol/l</td>
<td>8 (2)</td>
<td>1974</td>
</tr>
<tr>
<td>Mean 2 h insulin, pmol/l</td>
<td>425 (280)</td>
<td>1974</td>
</tr>
<tr>
<td>Fasting insulin secretion, pmol min⁻¹ m⁻²</td>
<td>103 (41)</td>
<td>1974</td>
</tr>
<tr>
<td>Glucose sensitivity, pmol min⁻¹ m⁻² mmol/L⁻¹</td>
<td>109 (55)</td>
<td>1974</td>
</tr>
<tr>
<td>Rate sensitivity, pmol m⁻² mmol/L⁻¹</td>
<td>833 (673)</td>
<td>1974</td>
</tr>
<tr>
<td>Potentiation factor ratio, dimensionless</td>
<td>2 (1)</td>
<td>1973</td>
</tr>
<tr>
<td>Integral of total insulin secretion, nmol/m²</td>
<td>50 (19)</td>
<td>1974</td>
</tr>
<tr>
<td>Insulin sensitivity (2 h OGIS), ml min⁻¹ m⁻²</td>
<td>369 (60.8)</td>
<td>1963</td>
</tr>
<tr>
<td>Stumvoll insulin sensitivity index, ml min⁻¹ kg⁻¹</td>
<td>7.6 (2.6)</td>
<td>1941</td>
</tr>
<tr>
<td>Matsuda insulin sensitivity index, arbitrary units</td>
<td>4.7 (3.1)</td>
<td>1974</td>
</tr>
</tbody>
</table>

Descriptive statistics shown are mean (SD) except for sex, which is n%. Values are untransformed and unadjusted. Follow-up Δ is mean (SD) of difference between characteristic value between follow-up assessment and baseline visits.
Here, we report the characteristics of the IMI DIRECT cohorts at baseline, at 18 months follow-up, and at 48 or 36 months follow-up (for cohorts 1 and 2 respectively) for glycaemic deterioration and consider these results in the context of the implemented protocols and the plans outlined in the design and rationale paper published previously [7]. The descriptive statistics, pairwise correlations and genetic substructures presented in this article are not intended for aetiological inference; instead, the purpose is to provide context and details for subsequent IMI DIRECT papers, as well as to inform scientists outside the Consortium who might in the future consider using the IMI DIRECT data in their research. Major advances in technologies and methods over the past decade make high-resolution quantification of disease phenotypes and processes possible in large sample collections. Applying modern assays to historical biosamples is particularly useful when studying processes that take decades to unfold. However, biosamples often degrade during long-term storage and many older studies did not deploy the advanced phenotyping methods available today. Recognising these limitations, we designed and initiated two state-of-the-art prospective cohort studies as part of the IMI DIRECT Consortium. Designed for biomarker discovery in glycaemic deterioration and diabetes progression, the IMI DIRECT cohorts include conventional and cutting-edge phenotyping techniques and technologies that are repeated on multiple occasions during a follow-up period of up to 48 months (currently ongoing). We note that the subsequent biomarker discovery analyses using these cohorts will combine the clinical phenotypic data described in this paper with omic measures such as transcriptomics (RNA sequencing from fasting whole blood), microbiomics (DNA isolation and deep sequencing in faecal samples), proteomics (targeted array in fasting plasma) and metabolomics (targeted and untargeted assays in fasting plasma).

Major advances in technologies and methods over the past decade make high-resolution quantification of disease phenotypes and processes possible in large sample collections. Applying modern assays to historical biosamples is particularly useful when studying processes that take decades to unfold. However, biosamples often degrade during long-term storage and many older studies did not deploy the advanced phenotyping methods available today. Recognising these limitations, we designed and initiated two state-of-the-art prospective cohort studies as part of the IMI DIRECT Consortium. Designed for biomarker discovery in glycaemic deterioration and diabetes progression, the IMI DIRECT cohorts include conventional and cutting-edge phenotyping techniques and technologies that are repeated on multiple occasions during a follow-up period of up to 48 months (currently ongoing). We note that the subsequent biomarker discovery analyses using these cohorts will combine the clinical phenotypic data described in this paper with omic measures such as transcriptomics (RNA sequencing from fasting whole blood), microbiomics (DNA isolation and deep sequencing in faecal samples), proteomics (targeted array in fasting plasma) and metabolomics (targeted and untargeted assays in fasting plasma).

The recruitment strategies for the two IMI DIRECT cohorts differed in that cohort 1 focused on recruiting participants from an existing large sample frame (N = 24,682) derived from established prospective cohort studies, whereas cohort

**Fig. 3** Pairwise correlation matrix of follow-up Δ (difference between 48 month follow-up assessment and baseline visit). Fill colour indicates Pearson correlation coefficient (r), where positive is denoted by red fill, inverse by blue fill and magnitude by intensity. Cohorts 1 and 2 are separate, above and below diagonal, respectively. All continuous variables were normally transformed and adjusted for age, sex and study centre. BasalISR, fasting insulin secretion; DBP, diastolic blood pressure; Glucose, fasting glucose; GlucoseSens, glucose sensitivity; Insulin, fasting insulin; Matsuda, Matsuda insulin sensitivity index; MeanGlucose, mean 2 h glucose; MeanInsulin, mean 2 h insulin; OGISH, insulin sensitivity (2 h OGISH); PFR, potentiation factor ratio; RateSens, rate sensitivity; SBP, systolic blood pressure; Stumvoll, Stumvoll insulin sensitivity index; TotalISR, integral of total insulin secretion; TwoGlucose, 2 h glucose; TwoInsulin, 2 h insulin.
though the generalisability of the study
the overall rate of glycaemic deterioration in the cohort, al-
size; in doing so, we recognised that this would likely reduce
lower-risk participants in order to achieve the target sample
the relatively large sampling frame, it was necessary to enrol
predict risk of rapid glycaemic deterioration. However, despite
studies for cohort 1 facilitated access to data that were used to
strategy for recruiting participants from existing prospective
2 used clinical registries to identify eligible participants. The
strategy for recruiting participants from existing prospective
studies for cohort 1 facilitated access to data that were used to
predict risk of rapid glycaemic deterioration. However, despite
the relatively large sampling frame, it was necessary to enrol
lower-risk participants in order to achieve the target sample
size; in doing so, we recognised that this would likely reduce the
overall rate of glycaemic deterioration in the cohort, al-
though the generalisability of the study’s findings will be
greater. In cohort 2, we fell slightly short of the target sample
size of 1000 participants (N = 789 with complete and high-
quality data eventually enrolled). This reflects the difficulties
in engaging some general practices, which was necessary to
access diabetes registries in some regions.

We stratified cohorts 1 and 2 by broad glucose-control
category (overtly normoglycaemic or impaired glycaemic reg-
ulation in any ADA category) or treatment category (lifestyle
only vs lifestyle plus metformin), respectively, to reflect the
basic stages of progression at baseline for descriptive purposes.

The two IMI DIRECT cohorts are not identical. However,
they share many methodology parallels that permit compli-
ant analyses to be performed, such as determining wheth-
er biomarkers for glycaemic deterioration are conditional on
disease state. Nevertheless, several key differences in the pro-
ocols (e.g. fsOGTT vs MMTT) should be considered when inter-
preting results. We also note a difference in missing
accelerometry (physical activity) data between cohort 1
(19%) and cohort 2 (8.5%); we were unable to definitively
explain this discrepancy. Partitioning change from error is
very challenging when variables are assessed at only two time
points owing to regression to the mean. Notwithstanding this,
we note a modest 0 month to 48 month difference in mean
(SD) fasting plasma glucose levels, 0.3 (0.5) mmol/l and 0.8
(1.9) mmol/l in cohort 1 and cohort 2, respectively (Table 2),
which likely reflects the relatively brief between-visit interval.
Furthermore, we note that the 0.5 mmol/l and 1.9 mmol/l SDs
in these differences, for cohort 1 and cohort 2, respectively,
suggest the potential heterogeneity in changes in glycaemic
control within each cohort. With this in mind, the IMI
DIRECT cohorts are being followed further with record-
linkage through 2026. It should also be noted that the IMI
DIRECT cohorts are predominantly of European ancestry;
therefore results from subsequent analyses on these cohorts
will need to be replicated in other cohorts of relevant ancestry
before generalising findings to other ethnicities. Finally, we
note that the results presented here reflect the data available at
publication and as long-term follow-up progresses additional
data will accrue.

Conclusion

The study described here is being used to unravel the heteroge-
eous nature of glycaemic deterioration in individuals at risk of
diabetes and in those with diabetes, and to discover biomarkers
that might prove useful for patient stratification and therapeutic
optimisation. As more prospective data are accrued, the IMI
DIRECT cohorts will grow in value. In the long term, the IMI
DIRECT Consortium intends to make these data available to
other researchers through a managed-access repository.

Acknowledgements

We thank all the participants and study centre staff
in IMI DIRECT for their contribution to the study. Some of the data were
presented as an abstract at the Precision Medicine in Type 2 Diabetes and
Cardiovascular Disease meeting in 2016 (Båstad, Sweden).

Data availability

Requests for access to IMI DIRECT data, including
data presented here, can made to DIRECTdataaccess@Dundee.ac.uk.

Funding

This work was supported by the Innovative Medicines Initiative
Joint Undertaking under grant agreement no. 115317 (DIRECT),
resources of which are composed of financial contribution from the
European Union’s Seventh Framework Programme (FP7/2007-2013)
and EFPIA companies in kind contribution. RWK was funded by a
STAR Award Novo Nordisk co-financed PhD fellowship. The work un-
dertaken by PWF was supported in part by programme grants from the
ERC-2015-CoG_NASCENT_681742 and the Swedish Research
Council; strategic funding for Lund University Diabetes Centre, where
some of the work described herein was performed, was provided by the
Swedish Research Council, Strategic Research Area Exodiab, (Dnr 2009-
1039), the Swedish Foundation for Strategic Research (IRC15-0067), the
Swedish Research Council, Linnaeus grant (Dnr 349-2006-237). EP
holds a Wellcome Trust Investigator award (grant reference 102820/Z/
13/2). Contributions to this work by SBru. were co-financed by the Novo
Nordisk Foundation (grants NNF17OC0027594 and NNF14CC0001).

Fig. 4 Genetic population structure within the cohorts. A statistical sum-
mary of genetic data from cohorts 1 and 2 (combined) based on principal
component axis one (PC1) and axis two (PC2). Points are coloured ac-
cording to recruitment centre

2
Duality of interest  The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement  RWK and PW were the manuscript. PW, MW and EP conceptualised and designed the studies, with contributions from RWK, IMF, HJAT, JA, JDB, JW, SMB, ETD, PF, GF, RG, AHa, BJ, TJM, OP, JMS, IP, AMar, MIMcM and HR. RWK carried out the statistical analyses presented here: RWK, AK, AV, MS, KHA, SMB, CAB, AYD, FDEM, CJG, TK, AM, MHP, SPR, ELT, AT, TW, HJAT, JA, JDB, JW, SMB, ETD, PF, GF, RG, ML, TJM, OP, JMS, AMar, MIMcM and EP and PW contributed to sample assaying, data analysis/processing and/or data quality control procedures. RWK, IMF, AHe, GNG, TTH, MH, ADMK, FR, MS, TK, MR, HJAT, HV, JDB, TH, AHa, ML, OP, MW, EP and PW contributed to data collection at study centres. PW coordinated the overall planning and implementation of the IMI DIRECT epidemiological studies. HR and EP were the overall coordinators of the IMI DIRECT Consortium. All authors contributed to the revision of the manuscript. All authors critiqued and approved the final version of the manuscript. All authors accept responsibility for all aspects of the work insofar as ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. PWF and EP are the guarantors of this work and, as such, had full access to the data described here and take responsibility for the integrity of the data and its analysis.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References


Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations


1 Department of Clinical Sciences, Lund University Diabetes Centre, Genetic and Molecular Epidemiology Unit, CRC, Skåne University Hospital Malmö, Building 91, Level 10, Jan Waldenströms gata 35, SE-205 02 Malmö, Sweden
2 Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
3 Population Health & Genomics, Medical Research Institute, University of Dundee, Dundee DD1 9SY, UK
4 Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
5 Institute of Genetics and Genomics in Geneva (iGE3), University of Geneva, Geneva, Switzerland
6 Swiss Institute of Bioinformatics, Geneva, Switzerland
7 Institute of Cellular Medicine (Diabetes), Newcastle University, Newcastle upon Tyne, UK
8 The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark
9 NIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK
10 Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, the Netherlands
11 Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
12 Department of Clinical Epidemiology, Bispebjerg and Frederiksberg Hospital, the Capital Region, Copenhagen, Denmark
13 MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK
14 Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
15 Department of Bio and Health Informatics, Technical University of Denmark, Lyngby, Denmark
16 Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
17 Department of Clinical Sciences, Clinical Obesity, Skåne University Hospital Malmö, Lund University, Malmö, Sweden
18 Novo Nordisk A/S, Søborg, Denmark
19 Novo Nordisk A/S, Søborg, Denmark
20 Novo Nordisk A/S, Søborg, Denmark
21 Novo Nordisk A/S, Søborg, Denmark
22 Novo Nordisk A/S, Søborg, Denmark
23 Novo Nordisk A/S, Søborg, Denmark
24 Novo Nordisk A/S, Søborg, Denmark
25 Novo Nordisk A/S, Søborg, Denmark
26 Novo Nordisk A/S, Søborg, Denmark
27 Novo Nordisk A/S, Søborg, Denmark
28 Novo Nordisk A/S, Søborg, Denmark
29 Novo Nordisk A/S, Søborg, Denmark
30 Novo Nordisk A/S, Søborg, Denmark
31 Novo Nordisk A/S, Søborg, Denmark
32 Novo Nordisk A/S, Søborg, Denmark
33 Novo Nordisk A/S, Søborg, Denmark

---

https://doi.org/10.2337/diacare.23.3.295
https://doi.org/10.1137/jc.2004-1133
https://doi.org/10.1038/nature07331
20 Research Centre for Optimal Health, Department of Life Sciences, University of Westminster, London, UK
21 Institute of Neurosciences, National Research Council, Padova, Italy
22 Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
23 The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark
24 Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, UK
25 CNRS, Pasteur Institute of Lille, University of Lille, Lille, France
26 Nutrition and Dietetics Research Group, Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London, Hammersmith Campus, London, UK
27 Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK
28 Sanofi-Aventis Deutschland GmbH, R&D, Frankfurt am Main, Germany
29 Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden
30 Eli Lilly Regional Operations GmbH, Vienna, Austria
31 NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK
32 Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
33 Department of Public Health & Clinical Medicine, Section for Medicine, Umeå University, Umeå, Sweden